1 There is evidence for interactions between mu and delta opioid systems both in vitro and in vivo. This work examines the hypothesis that interaction between these two receptors can occur intracellularly at the level of G protein in human neuroblastoma SH-SY5Y cells. 4 Tolerance to DAMGO and SNC80 in membranes from cells exposed to agonist for 18 h was homologous and there was no evidence for alteration in G protein activity. 5 The ®ndings support the hypothesis that mu-and delta-opioid receptors share a common G protein pool, possibly through a close organization of the two receptors and G protein at the plasma membrane.
Introduction
Opioid mu and delta receptors couple to pertussis toxin sensitive G proteins (Uhl et al., 1993) , which inhibit adenylyl cyclase. Selective agonists at the mu and delta receptors have their own distinct characteristics and pharmacology, though there is evidence for cross-talk between the two receptor types. This comes from ligand binding assays and pharmacological assays including antinociception, bladder contraction, antitussive activity and inhibition of gut propulsion (for review see Traynor & Elliott, 1993) , although cross-talk is not apparent in isolated tissue preparations (Elliott & Traynor, 1995; Matthes et al., 1998) . In addition, there is evidence of a role for the delta opioid system in the development of tolerance to mu-opioid agonists (Abdelhamid et al., 1991; Kest et al., 1996; Hepburn et al., 1997) .
More recently these interactions have been highlighted with the availability of opioid receptor knockout mice. Delta analgesia and respiratory depression are reported to be reduced in mu-receptor knockout mice (Matthes et al., 1998) and there is con®rmation of a role for the delta system in mutolerance from studies with delta-receptor knockout mice (Zhu et al., 1999) . Finally, there is evidence for the presence of mu-/ delta-receptor interactions when both receptors are co-expressed in GH 3 cells (Martin & Prather, 2001 ) and evidence for hetero -dimers or -oligomers when both receptors are expressed in COS-7 (George et al., 2000) or HEK-293 (Gomes et al., 2000) cells, resulting in receptors with dierent ligand binding and functional properties.
Intracellular cross-talk mechanisms between receptors could occur at the level of G protein (Kenakin & Morgan, 1989) . For example, in membranes from turkey erythrocytes and rat adipocytes dierent Gs-coupled receptors share a common G protein pool (Pike & Lefkowitz, 1981; Murayama & Ui, 1984) , and in hamster adipocyctes dierent Gi-coupled receptors can access the same G proteins (Murayama & Ui, 1984) . Both mu-and delta-opioid receptors couple to similarwas designed to test the hypothesis that mu and delta receptors activate the same individual G proteins in cells that express both receptor types and this provides a focus for interaction. Human neuroblastoma SH-SY5Y cells were chosen for this study because they endogenously express both mu-and delta-opioid receptors (Kazmi & Mishra, 1987) that couple to similar eectors. For example, in SH-SY5Y cells agonist occupation of both receptor types leads to inhibition of adenylyl cyclase and, in dierentiated SH-SY5Y cells, inhibition of o-conotoxin-sensitive Ca 2+ channels (Toselli et al., 1997) and mobilization of Ca 2+ from intracellular stores (Connor & Henderson, 1996) .
Opioid-receptor-mediated activation of G proteins stimulates the binding of [ 35 S]-GTPgS to G proteins in SH-SY5Y membranes (Traynor & Nahorski, 1995 (Hilf et al., 1992) and cannabinoid (Breivogel et al., 1998 ]-GTPgS binding to G protein as a result of mu-or delta-receptor activation can be caused to dissociate by either a mu-or a delta-agonist. Taken together these ®ndings strongly support the hypothesis that mu-and delta-opioid receptors share a common G protein pool and this provides an intracellular mechanism for interaction between these two receptors. 
Methods

Chemicals and drugs
Cell culture
SH-SY5Y cells and C 6 rat glioma cells stably transfected with a rat mu (C 6 (m)) or delta (C 6 (d)) opioid receptor (Lee et al., 1999) Geneticin. Cells used for experiments were grown in the absence of Geneticin without a signi®cant loss in receptor density. For the study of tolerance, cells were grown in the presence of DAMGO (1 mM) or SNC80 (1 mM) or vehicle for 18 h prior to harvest. Compounds were added in a sterile water/DMSO vehicle such that the ®nal DMSO concentration was 0.01%.
Membrane preparation
Cells were rinsed twice with ice-cold phosphate-buered saline (0.9% NaCl, 0.61 mM Na 2 HPO 4 , 0.38 mM KH 2 PO 4 , pH 7.4), detached from dishes by incubation with lifting buer (mM: glucose 5.6, KCl 5, HEPES 5, NaCl 137, EGTA 1, pH 7.4) and collected by centrifugation (5006g). The cells were resuspended in ice-cold lysis buer (0.2 mM MgSO 4 , 0.38 mM KH 2 PO 4 , 0.61 mM Na 2 HPO 4 , pH 7.4) and homogenized using a glass-glass Dounce homogenizer. Crude membranes were isolated by centrifugation for 20 min at 20,0006g. The resulting membrane pellets were resuspended in 50 mM Tris-HCl buer (pH 7.4) and stored at 7808C in 500 ml aliquots containing 0.5 mg protein (Bradford, 1976) . All procedures were performed at 48C. (pH 7.4) or GTPgS binding buer (mM: Tris 50, NaCl 100, MgCl 2 5, EDTA 1, dithiothreitol 1, pH 7.4) containing 30 mM GDP. The reactions were terminated by the addition of 2 ml ice-cold Tris-HCl buer. The contents of the tubes were then rapidly vacuum-®ltered through glass ®bre ®lters (Schleicher & Schuell no.32, Keene, NH, U.S.A.) and the tubes and ®lters rinsed with ice-cold 3 ml Tris-HCl an additional three times. Radioactivity retained by the ®lters was determined by liquid scintillation counting. Non-speci®c binding was de®ned with 10 mM naloxone.
Ligand-binding assays
Cyclic AMP assay
SH-SY5Y cells were grown in 24-well plates for 24 h to con¯uency as described above. The culture medium was then replaced with DMEM without foetal bovine serum, followed by replacement of the media with DMEM at 378 containing 1.0 mM IBMX, 30 mM forskolin with or without appropriate opioid agonist. After 30 min at 378, the assay was stopped by removing the assay medium and replacing with 1 ml ice cold 3% perchloric acid. After at least 30 min at 48, a 400 ml aliquot was removed from each well, neutralized with 75 ml 2.5 M KHCO 3 and centrifuged for 1 min at 15,0006g. A radioimmunoassay kit was used to quantify accumulated cyclic AMP in a 10 ml aliquot of the supernatant from each sample. Inhibition of cyclic AMP formation was determined as a per cent of forskolin-stimulated cyclic AMP accumulation in the absence of opioid agonist.
[
S]GTPgS binding
Membranes ( ]GTPgS for 60 min at 258C, in the absence or presence of varying concentrations of agonist, in GTPgS binding buer (®nal concentration mM: Tris 50, NaCl 100, MgCl 2 5, EDTA 1, dithiothreitol 1, GDP 50 mM, pH 7.4) in a ®nal assay volume of 400 ml. Reactions were terminated by the addition of 2 ml ice-cold washing buer (mM: Tris 50, NaCl 100, MgCl 2 5, pH 7.4), followed by rapid ®ltration as above. The tubes and ®lters were rinsed three times with 3 ml ice-cold washing buer and bound ligand determined by scintillation counting. 
Data analysis
Graph Pad Prism (San Diego, CA, U.S.A.) was used to perform linear and nonlinear regression analysis of the data. Ligand saturation binding data were analysed using a onesite saturation binding equation. Concentration response curves for [ 
Results
Ligand binding
Adenylyl cyclase
Cyclic AMP accumulation stimulated by forskolin was reduced to 65.3+3.2% by 1 mM DAMGO and to 86.2+4.8% by 1 mM SNC80. The addition of SNC80 (1 mM) and DAMGO (1 mM) together did not increase the level of cyclic AMP inhibited by DAMGO alone (65.4+3.3%). To verify that DAMGO and SNC80 produced their eects by selectively acting at mu and delta receptors respectively, concentration-response curves were determined in the presence of the mu-selective antagonist CTAP (Pelton et al., 1986) or the delta-selective antagonist TIPP[c] (Schiller et al., 1993) . Addition of 300 nM CTAP shifted the DAMGO concentration-response curve 47 fold (Figure 2A ), but produced only a statistically insigni®cant 1.5 fold shift in the SNC80 concentration-response curve ( Figure 2B ).
Conversely, 10 mM TIPP[c] completely blocked the eect of SNC80 at concentrations up to 10 mM ( Figure 2C ) but Figure 2D ). The selectivity of DAMGO and SNC80 for the mu and delta opioid receptors respectively was con®rmed in membranes from C 6 rat glioma cells stably expressing cloned mu or delta opioid receptors. In C 6 (m) cell membranes, DAMGO stimulated [ 35 S]-GTPgS binding with potency similar to that seen in SH-SY5Y membranes (EC 50 =32 nM, 95% C.I., 13 ± 76 nM) but SNC80 at concentrations up to 10 mM had no signi®cant eect (9+9% of maximal DAMGO stimulation). Conversely, in C 6 (d) cell membranes, SNC80 stimulated [ 35 S]-GTPgS binding with an EC 50 of 18 nM (95% C.I., 6 ± 56 nM), but DAMGO had no appreciable eect at concentrations up to 10 mM, producing only 4+1% of the maximal SNC80 stimulation.
To test the hypothesis that mu and delta opioid receptors share a common pool of G proteins, the additivity of G protein activation by DAMGO and SNC80 in SH-SY5Y cell membranes was measured. When maximally eective concentrations of DAMGO and SNC80 were combined, the level of [ SNC80 alone produced 50+4% of the eect aorded by 10 mM DAMGO. When 10 mM SNC80 was combined with 10 mM DAMGO, the total G protein activation totalled 108+4% of that produced by DAMGO alone. Values are means+s.e.mean from three independent experiments carried out in duplicate.
British Journal of Pharmacology vol 135 (1)
Opioid receptor cross-talk A. Alt et al However, addition of 1 mM DAMGO increased the dissociation rate to a similar rate as seen in the presence of 1 mM SNC80 alone (t 1/2 =11+1 min), with a maximal dissociation of 77+5% of the bound [ 
Tolerance
To determine whether cross-tolerance is exhibited between mu and delta agonists in this system, SH-SY5Y cells were treated for 18 h in the presence or absence of 1 mM DAMGO or 1 mM SNC80 prior to harvesting and membrane preparation. S]GTPgS binding in membranes from cells treated chronically with DAMGO was only 55+4% of that seen in control cells, but with no signi®cant change in EC 50 . The EC 50 value for DAMGO was 25 nM (95% C.I., 11 ± 54 nM) in membranes from chronic DAMGO-treated cells versus 23 nM (95% C.I., 13 ± 38 nM) in membranes from cells treated with vehicle only ( Figure 5A ). The SNC80 concentration-response curve was not signi®-cantly aected by 18 h DAMGO treatment. Thus, in membranes from DAMGO-treated cells maximal [ 35 S]-GTPgS binding was equal to 97+5% of that seen in untreated cells and there was no change in the EC 50 (10 nM, 95% C.I., 7 ± 14 nM versus 9 nM, 95% C.I., 5 ± 17 nM in control membranes; Figure 5B ).
Chronic treatment of cells with SNC80 resulted in a complete insensitivity of membranes to subsequent SNC80 administration at concentrations up to 10 mM ( Figure 5C ), with no eect on the DAMGO concentration-response curve ( Figure 5D ). Maximal DAMGO stimulation of [ 
Discussion
Mu and delta opioid receptors can activate the same inhibitory G protein subtypes (Prather et al., 1994a; Chakrabarti et al., 1995) although in SH-SY5Y human neuroblastoma cells mu and delta receptors do show a dierent preference for Ga subunits (Laugwitz et al., 1993) . The current study was designed to test the hypothesis that mu and delta receptors share a common pool of G proteins and that at full receptor occupancy the receptors compete for G protein.
The mu-selective agonist DAMGO and the delta-selective agonist SNC80 stimulated [ 35 S]-GTPgS binding in a concentration-dependent manner in SH-SY5Y cells. SNC80 produced 57+5% of the maximum eect seen with DAMGO, consistent with the 1 : 2 ratio of total delta to mu receptors as measured in Tris buer. In the presence of the more complex buer containing Na + ions and GDP the measured number of mu and delta receptors was equivalent, but much reduced, together with a reduction in ligand anity. This suggests the total receptor number, rather than the number of receptors in a particular anity state, governs the maximal level of [ ]-GTPgS and 1 mM DAMGO to label mu-sensitive G proteins, as described in Methods. At time zero, dissociation was initiated by the addition of 50 mM unlabelled GTPgS in the absence or presence of 300 nM CTAP or 300 nM CTAP+1 mM SNC80. (B) Delta-sensitive G proteins were labelled using 1 mM SNC80. To start dissociation, 50 mM unlabelled GTPgS was added in the absence or presence of 3 mM TIPP[c], orWhen maximally eective concentrations of DAMGO and SNC80 were combined, the eect produced was not signi®cantly greater than that produced by DAMGO alone determined either by stimulation of [ 35 S]-GTPgS binding or by the inhibition of cyclic AMP accumulation, indicating that agonist-occupied mu and delta receptors activate common G proteins. This conclusion was con®rmed by the ability of agonists speci®c for either receptor to aord dissociation of [ 35 S]-GTPgS that had been caused to bind to G protein asubunits by either a mu or a delta agonist. Indeed, the ability of both mu and delta agonists to cause dissociation suggests the [ 35 S]-GTPgS-occupied Ga subunit remains accessible to both mu and delta receptors, such that both receptors can access the C-terminus of the Ga subunit that is important for receptor-G protein coupling (Conklin et al., 1993) . This conclusion is supported by studies demonstrating a persistent membrane localization of Ga 1 throughout the cycle of G protein activation (Huang et al., 1999) and the ability of receptor-G protein fusion proteins to interact with adenylyl cyclase (Bertin et al., 1994; Milligan, 2000) . Alternatively the dissociation of bound [ 35 S]-GTPgS could be through an indirect mechanism. Gbg is known to promote the dissociation of [ 35 S]-GTPgS from puri®ed Gao and Gai subunits and this process is inhibited by Mg 2+ (Sternweis & Robishaw, 1984; Higashijima et al., 1987) . It is feasible that in native membranes [ (Breivogel et al., 1998) .
The simplest explanation for the ability of DAMGO and SNC80 to activate the same G proteins would be if either or both ligands lack receptor selectivity. However, this explanation can be ruled out based on the eects of the selective antagonists CTAP and TIPP[c] on agonist-induced [ 35 S]-GTPgS binding, and on the highly mu-selective action of DAMGO and delta-selective action of SNC80 in membranes from C 6 cells expressing a single receptor type.
The ®nding that mu and delta receptors share G proteins in SH-SY5Y cell membranes could indicate access of the receptors to the complete inhibitory G protein pool, as for example with G i -coupled receptors in hamster adipocyte membranes (Murayama & Ui, 1984) . However, there is evidence for compartmentalization of signalling in SH-SY5Y cells with each receptor able to activate approximately four G proteins (Remmers et al., 2000) and that the number of G protein activated depends upon the receptor concentration. The observation that maximal delta-agonist mediated G protein activation was only half of that produced by agonist occupation of the mu receptors indicates either that delta receptors cannot access the entire G protein pool available to mu receptors or that one or more species of mu receptorsensitive G proteins exist which are relatively insensitive to delta receptor activation.
The ®ndings are also consistent with a model in which mu and delta receptors are associated in a mu-delta complex (Vaught et al., 1982) although the evidence for such a complex has remained indirect (Traynor & Elliott, 1993) . More recently, opioid receptors have been shown to form homo- (Cvejic & Devi, 1997) , and hetero-oligomers (Jordan & Devi, 1999; George et al., 2000; Gomes et al., 2000) . The ability of mu and delta receptors to share individual G proteins in the current study may indicate that the receptors are in close physical proximity to each other, and it is tempting to speculate that these opioid receptors exist as heterooligomers in SH-SY5Y cell membranes. Certainly, mu and delta receptors form heterooligomers when co-expressed in COS-7 cells and such heterooligomers have unique properties (George et al., 2000) . However, there is no evidence for a new signalling entity composed of mu and delta receptors in the SH-SY5Y cell membranes employed in this study. Firstly, the EC 50 for stimulation of [ (Gomes et al., 2001) . Thus, our results suggest that in human neuroblastoma SH-SY5Y cells mu and delta receptors access the same G proteins without necessarily forming hetero-complexes or a new signalling entity.
The ability of mu and delta opioid receptors to activate the same pool of G proteins could explain reported mu delta interactions. For example, in certain in vivo systems the potency and ecacy of morphine, but not higher ecacy agonists such as DAMGO, is increased by sub-eective concentrations of DPDPE or Leu-enkephalin (Vaught et al., 1982; Heyman et al., 1989a; Sheldon et al., 1989; Jiang et al., 1990) . Since some cells do co-express both mu and delta receptors (Ji et al., 1995) this may be caused by addition of the stimulatory eects of mu and delta agonists on G protein or by a`priming' of G protein by the delta agonists. Presumably such interaction would also occur in the opposite direction and so could contribute to the modulation of spinal analgesia and the lack of delta-mediated respiratory depression in mu-receptor knock-out mice. However, the observation that the delta agonists Met-enkephalin and Metenkephalinamide inhibit morphine antinociception (Vaught & Takemori, 1979; Vaught et al., 1982; Heyman et al., 1989b; Jiang et al., 1990 ) is dicult to explain with this model.
Prolonged exposure of opioid receptors to agonist is known to produce a state of tolerance which includes uncoupling of receptor and G protein, receptor downregulation and compensatory changes in downstream eectors. Although mu and delta receptors share G proteins in SH-SY5Y membranes, tolerance was seen to be homologous and therefore occurred at the receptor, rather than at the G protein. Chronic DAMGO treatment of SH-SY5Y cells results in a reduction in receptor number (Elliott et al., 1997) but it can be inferred that the majority of G proteins remained fully functional, since SNC80 still produced its full G protein activation in the face of tolerance to DAMGO and vice-versa. This is consistent with ®ndings that functional coupling of the delta opioid receptor is not altered in mureceptor knockout mice (Matthes et al., 1998) . Furthermore the ®ndings agree with previous reports that opioid tolerance is homologous in SH-SY5Y cells, both in terms of receptor down-regulation (Zadina et al., 1994) , and desensitization of the adenylyl cyclase response (Prather et al., 1994b) .
In SK-N-SH, the parent cell line of SH-SY5Y cells, which express mu and delta receptors, mu and delta opioid receptor down-regulation is also homologous (Baumhaker et al., 1993) . However, in SK-N-SH cells there is no evidence for cross-talk at the level of G protein and each receptor appears to activate a separate pool of G proteins (Shapiro et al., 2000) . When transfected into COS-7 cells mu and delta receptors do share a common pool of G proteins and so Shapiro et al. (2000) suggest the ®ndings are due to dierences between transfected cell lines, where receptors show promiscuous coupling, and cells which natively express mu and delta opioid receptors. Our results with mu and delta receptors endogenously expressed in SH-SY5Y cells suggest dierences between this cell and its parent SK-N-SH and thus do not support this conclusion. The results, however, do support the broader concept that cellular organization is important in governing which signal transduction pathways are activated by a particular receptor and so varies across cell types.
In conclusion, the data presented con®rm that although mu and delta receptors may prefer particular Gi/Go subtypes there is no absolute speci®city governed by receptor structure. The ®ndings provide strong evidence for a common activation of G protein by mu and delta opioid receptors in SH-SY5Y human neuroblastoma cells that may play a role in the pharmacology of mu and delta opioid receptors. Moreover the results are consistent with a compartmental organization of mu receptors, delta receptors and G protein for the control of receptor signalling.
